Search

everythinglearnresearchcommunity

for

Search:↓

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.

RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

A joke about creating a hair loss treatment in the kitchen, with replies encouraging more jokes.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Mixing RU58841 with a solution for hair loss treatment, with suggestions to use propylene glycol and ethanol instead of k&b solution due to scalp irritation. Recommendations include using ketoconazole shampoo for itchiness and considering oral minoxidil if topical causes irritation.

Sodium Laureth Sulfate (SLS) in shampoos and its potential impact on thinning hair. The user follows a regimen of shampoo, keto shampoo, and conditioner, seeking suggestions for better products.

The conversation is about someone seeking information on long-term users of CB-03-01 for hair loss, having experienced negative side effects from finasteride and facing rapid hair thinning.

The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.

Pyrilutamide is being used effectively for hair loss with no side effects, and the user is seeking a cheaper bulk supplier. Users discuss the difficulty of finding affordable, trustworthy sources, with some suggesting potential suppliers.

The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.

Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.

The ineffectiveness of Strut Health's dutasteride capsules, which are filled with raw powder instead of liquid and don't contain any buffering agents that would allow for absorption into the bloodstream. It is suggested to use other brands of liquid-filled dutasteride capsules for better results.

A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

The user experienced severe side effects from finasteride, including panic attacks and suicidal thoughts, and is seeking alternative hair loss treatments. They have been using oral finasteride and topical minoxidil.

The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

A dermatologist recommended switching from finasteride to dutasteride due to concerns about finasteride's side effects, despite the user not experiencing any. The user is considering transitioning strategies, including stopping finasteride immediately or overlapping both medications.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

The conversation is about difficulty finding a reputable source for Latanoprost or Bimatoprost in pure powder form or high concentrations for hair loss treatment, with only low concentration solutions being readily available.

The conversation discusses combining topical cetirizine with minoxidil for hair loss treatment and inquires about the safety and absorption through the skin, as well as the possibility of adding melatonin.